0000920465-20-000139.txt : 20200902
0000920465-20-000139.hdr.sgml : 20200902
20200902161722
ACCESSION NUMBER: 0000920465-20-000139
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200831
FILED AS OF DATE: 20200902
DATE AS OF CHANGE: 20200902
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Chawla Lakhmir S
CENTRAL INDEX KEY: 0001646626
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36282
FILM NUMBER: 201157112
MAIL ADDRESS:
STREET 1: 1960 KIRBY ROAD
CITY: MCLEAN
STATE: VA
ZIP: 22101
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: LA JOLLA PHARMACEUTICAL CO
CENTRAL INDEX KEY: 0000920465
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 330361285
STATE OF INCORPORATION: CA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 4550 TOWNE CENTRE COURT
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-207-4264
MAIL ADDRESS:
STREET 1: 4550 TOWNE CENTRE COURT
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
wf-form4_159907782635396.xml
FORM 4
X0306
4
2020-08-31
0
0000920465
LA JOLLA PHARMACEUTICAL CO
LJPC
0001646626
Chawla Lakhmir S
C/O LA JOLLA PHARMACEUTICAL COMPANY,
4747 EXECUTIVE DRIVE, SUITE 240
SAN DIEGO
CA
92121
0
1
0
0
Chief Medical Officer
Common Stock
2020-08-31
4
A
0
550
3.57
A
13161
D
Employee Stock Option (Right to Buy)
4.2
2020-08-31
4
A
0
550
0
A
2030-08-31
Common Stock
550.0
550
D
These shares were acquired on 08/31/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
The stock options vest and become exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vest and become exercisable ratably on a monthly basis over the next three years.
/s/ Ryan Murr, as attorney-in-fact for Lakhmir Chawla
2020-09-02